Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xingfeng Bao

Showing results (21-30 of 26) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 26 results.
Molecular Cancer Therapeutics|March 21, 2022
Pharmacologic Activation of STING in the Bladder Induces Potent Antitumor Immunity in Non-Muscle Invasive Murine Bladder CancerKuan-Chun Huang, Dinesh Chanda, Shannon McGrath, et al.
Journal for Immunotherapy of Cancer|June 20, 2020
First-in-human phase I study of immunomodulatory E7046, an antagonist of PGE<sub>2</sub>-receptor E-type 4 (EP4), in patients with advanced cancersDavid S Hong, Aparna Parikh, Geoffrey I Shapiro, et al.
Molecular Cancer Therapeutics|April 3, 2023
Correction: Pharmacologic Activation of STING in the Bladder Induces Potent Antitumor Immunity in Non-Muscle Invasive Murine Bladder CancerKuan-Chun Huang, Dinesh Chandra, Shannon McGrath, et al.
Chemmedchem|February 1, 2021
E7766, a Macrocycle-Bridged Stimulator of Interferon Genes (STING) Agonist with Potent Pan-Genotypic ActivityDae-Shik Kim, Atsushi Endo, Francis G Fang, et al.
Cancer Biology & Therapy|March 3, 2015
Small molecule schweinfurthins selectively inhibit cancer cell proliferation and mTOR/AKT signaling by interfering with trans-Golgi-network traffickingXingfeng Bao, Wanjun Zheng, Naoko Hata Sugi, et al.
Cell|April 24, 2024
IGSF8 is an innate immune checkpoint and cancer immunotherapy targetYulong Li, Xiangyang Wu, Caibin Sheng, et al.
Pageof 3

Showing results (21-30 of 26) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 26 results.
Molecular Cancer Therapeutics|March 21, 2022
Pharmacologic Activation of STING in the Bladder Induces Potent Antitumor Immunity in Non-Muscle Invasive Murine Bladder CancerKuan-Chun Huang, Dinesh Chanda, Shannon McGrath, et al.
Journal for Immunotherapy of Cancer|June 20, 2020
First-in-human phase I study of immunomodulatory E7046, an antagonist of PGE<sub>2</sub>-receptor E-type 4 (EP4), in patients with advanced cancersDavid S Hong, Aparna Parikh, Geoffrey I Shapiro, et al.
Molecular Cancer Therapeutics|April 3, 2023
Correction: Pharmacologic Activation of STING in the Bladder Induces Potent Antitumor Immunity in Non-Muscle Invasive Murine Bladder CancerKuan-Chun Huang, Dinesh Chandra, Shannon McGrath, et al.
Chemmedchem|February 1, 2021
E7766, a Macrocycle-Bridged Stimulator of Interferon Genes (STING) Agonist with Potent Pan-Genotypic ActivityDae-Shik Kim, Atsushi Endo, Francis G Fang, et al.
Cancer Biology & Therapy|March 3, 2015
Small molecule schweinfurthins selectively inhibit cancer cell proliferation and mTOR/AKT signaling by interfering with trans-Golgi-network traffickingXingfeng Bao, Wanjun Zheng, Naoko Hata Sugi, et al.
Cell|April 24, 2024
IGSF8 is an innate immune checkpoint and cancer immunotherapy targetYulong Li, Xiangyang Wu, Caibin Sheng, et al.
Pageof 3